NCT05633303Recruiting
Personalised Ablation Strategies in AF
Developing Dynamic Substrate Targeted Personalised Treatment Strategies in AF.
Source: ClinicalTrials.gov · Last updated 8 May 2026
Brief summary (registry, in English)
Atrial fibrillation (AF) is the most common arrhythmia with an expected rise in prevalence over the next decade. Catheter ablation is a safe treatment option in eliminating AF however, success rates still remains variable. Existing strategies do not take into account the differences in AF perpetuation mechanisms beyond the pulmonary veins (PVs) due to the underlying substrate. Here, I will investigate the differences in persistent AF mechanisms due to the underlying substrate and utilise these findings to generate AF mechanism specific ablation strategies. I have defined a new metric, rate-dependent conduction velocity (RDCV) slowing that has shown to correlate with sites of re-entry activity in AF. In this study, techniques and methods will be developed to measure RDCV slowing sites. The impact autonomic modulation has on AF mechanisms and CV dynamics will also be assessed. The hypothesis is that a combination of structural, electrical and autonomic remodelling play an important mechanistic role in persistent AF and ablation strategies adapted to target these will result in greater procedural success rate. The study findings have the potential to improve the success rate of catheter ablation in persistent AF thereby improve patient wellbeing and reduce the cost burden of AF treatment.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- First submitted
- 10 Oct 2022
- Start date
- 14 Oct 2022
- Primary completion date
- 10 Oct 2027
- Lead sponsor
- Barts & The London NHS Trust
- Diseases
- Atrial fibrillation
- NCT number
- NCT05633303
What you commit to
- Study type: Interventional
- Planned participants: 160
- From 14 Oct 2022 to the primary completion date, 10 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \<18 years
Other
- Unwillingness to sign consent
- Contraindications for catheter ablation procedure
Who the study is looking for
- Patients undergoing catheter ablation for persistent AF (\<24 months AF duration and no previous left atrial ablation).
- Able to provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Barts Heart Centre, Barts Health NHS trust Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.